BOSTON—As more targeted therapies for non–small-cell lung cancer (NSCLC) become available, experts are assessing which patients’ tumors should be genotyped and when. Although genotyping—not to be confused with genetic testing—is becoming increasingly important in developing a treatment plan, professional guidelines do not yet recommend incorporating it as a routine part of care for patients with NSCLC.
BOSTON—Recognizing steroid-induced hyperglycemia early and addressing it promptly can prevent significant adverse effects associated with this complication. Educating patients on the importance of and methods for maintaining good blood glucose control helps mitigate damage to the vascular system and kidneys from hyperglycemia. It also lessens susceptibility to infection, a complication of hyperglycemia that is of serious concern in immunocompromised patients.
Breast cancer is the most common cancer among women. In 2010, there were an estimated 207,090 new cases and 39,840 deaths.1 Despite many improvements in the treatment of breast cancer, about 20% to 30% of women with the disease will progress to metastatic breast cancer (MBC). Although MBC remains incurable, a variety of treatment options are available. The US Food and Drug Administration (FDA) recently approved eribulin (Halaven), providing an exciting new option for women with heavily pretreated MBC.
Poly(ADP-ribose) polymerase (PARP) are a group of enzymes that are essential for base excision repair.1 There are several members of the PARP family, of which PARP1 is the most extensively studied.1,2 PARP1 only detects single-stranded DNA breaks and initiates repair; without PARP1, a single-stranded break is converted into a double-stranded break and repaired by homologous repair.1 PARP inhibition shows promise in BRCA1/2- deficient tumors, which lack homologous repair capability, causing synthetic lethality (decrease in repair of both single- and double-st Read More ›
ACOSOG Z1031: Neoadjuvant Comparison between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Rich Stage 2/3 Breast Cancer Read More ›
Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.
